These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21372265)

  • 1. Iron overload as cardiovascular risk factor in children and adolescents with renal disease.
    Ruiz-Jaramillo Mde L; Guízar-Mendoza JM; Amador-Licona N; Gutiérrez-Navarro Mde J; Hernández-González MA; Dubey-Ortega LA; Solorio-Meza SE
    Nephrol Dial Transplant; 2011 Oct; 26(10):3268-73. PubMed ID: 21372265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation.
    David S; Kümpers P; Hellpap J; Horn R; Leitolf H; Haller H; Kielstein JT
    Am J Kidney Dis; 2009 May; 53(5):770-8. PubMed ID: 19268412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceruloplasmin and acute phase protein levels are associated with cardiovascular disease in chronic dialysis patients.
    Panichi V; Taccola D; Rizza GM; Consani C; Migliori M; Filippi C; Paoletti S; Sidoti A; Borracelli D; Panicucci E; Giovannini L
    J Nephrol; 2004; 17(5):715-20. PubMed ID: 15593040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease.
    Inati A; Musallam KM; Wood JC; Sheikh-Taha M; Daou L; Taher AT
    Eur J Haematol; 2009 Dec; 83(6):565-71. PubMed ID: 19737308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study.
    Li XY; Chang JP; Su ZW; Li JH; Peng BS; Zhu SL; Cai AJ; Zhang J; Jiang Y
    Ther Apher Dial; 2010 Jun; 14(3):308-14. PubMed ID: 20609184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of dialysis type on biomarkers for cardiovascular diseases.
    Sahinarslan A; Güz G; Mutluay R; Okyay K; Demirtaş C; Paşaoğlu H; Yalçın R
    Turk Kardiyol Dern Ars; 2011 Sep; 39(6):456-62. PubMed ID: 21918314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels.
    Borazan A; Ustün H; Ustundag Y; Aydemir S; Bayraktaroglu T; Sert M; Yilmaz A
    Mediators Inflamm; 2004 Jun; 13(3):201-4. PubMed ID: 15223612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between circulating electronegative low-density lipoproteins and serum ferritin in hemodialysis patients: a pilot study.
    Lobo JC; Farage NE; Abdalla DS; Velarde LG; Torres JP; Mafra D
    J Ren Nutr; 2012 May; 22(3):350-6. PubMed ID: 21741859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of inflammatory factors and cardiac troponin T in hemodialysis patients.
    Falaknazi K; Bagheri N; Taziki O
    Saudi J Kidney Dis Transpl; 2009 Mar; 20(2):219-22. PubMed ID: 19237807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive correlation of CRP and fibrinogen levels as cardiovascular risk factors in early stage of continuous ambulatory peritoneal dialysis patients.
    Tekin IO; Pocan B; Borazan A; Ucar E; Kuvandik G; Ilikhan S; Demircan N; Ozer C; Kadayifci S
    Ren Fail; 2008; 30(2):219-25. PubMed ID: 18300125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies.
    Kim YR; Kim JS; Cheong JW; Song JW; Min YH
    Acta Haematol; 2008; 120(3):182-9. PubMed ID: 19129689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.
    Helal I; Smaoui W; Hamida FB; Ouniss M; Aderrahim E; Hedri H; Elyounsi F; Maiz HB; Abdallah TB; Kheder A
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):59-62. PubMed ID: 20061694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are metalloproteins and acute phase reactants associated with cardiovascular disease in end-stage renal failure?
    Healy H; Reith D; Morgan C; Clague A; Westhuyzen J
    Ann Clin Lab Sci; 2000 Jul; 30(3):295-304. PubMed ID: 10945571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)].
    Portolés J; López-Gómez JM; Aljama P
    Nefrologia; 2005; 25(3):297-306. PubMed ID: 16053011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain natriuretic peptide between traditional and nontraditional risk factors in hemodialysis patients: analysis of cardiovascular mortality in a two-year follow-up.
    Selim G; Stojceva-Taneva O; Spasovski G; Georgievska-Ismail L; Zafirovska-Ivanovska B; Gelev S; Dzekova P; Trajcevska L; Trojacanec-Piponska S; Sikole A
    Nephron Clin Pract; 2011; 119(2):c162-70. PubMed ID: 21757955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body mass index and cardiovascular risk factors and biomarkers in hemodialysis patients.
    Bossola M; Giungi S; Panocchia N; Vulpio C; Luciani G; Tazza L
    J Nephrol; 2008; 21(2):197-204. PubMed ID: 18446714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron status and cardiovascular risk factors in patients with haemodialysis versus patients with ischaemic heart disease.
    Cheng YC; Kuo WW; Wu CH; Shu WT; Kuo CH; Hwang JM; Hsu HH; Chen LM; Huang CY; Lee SD
    Nephrology (Carlton); 2009 Feb; 14(1):65-9. PubMed ID: 19054334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between epicardial adipose tissue, inflammation and volume markers in hemodialysis and transplant patients.
    Çolak H; Kilicarslan B; Tekce H; Tanrisev M; Tugmen C; Aktas G; Kursat S
    Ther Apher Dial; 2015 Feb; 19(1):56-62. PubMed ID: 25628169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.